top of page
PROVISCUS® is derived from human umbilical cord tissue and it is intended as a cushioning agent for homologous supplementation.
Advantages:
-
Wharton’s Jelly does not exhibit an immune reaction or rejection and is considered “immune privileged”.
-
Our proprietary BioRetain™ process does not alter the original tissue’s function for providing physical support and cushioning.
Features:
-
PROVISCUS® is minimally manipulated to preserve the endogenous components of Wharton’s Jelly.
-
Wharton’s Jelly provides cushioning, support and lubrication, and is the only tissue allograft which has the structure to perform all of these functions.
Product Information
PROVISCUS® is a perinatal tissue-derived allograft. It is designated as a Human Cell, Tissue, and Cellular and Tissue-Based Product (HCT/P) by the U.S. Food and Drug Administration (FDA), is minimally manipulated, and is produced in accordance with the FDA regulations for Good Tissue Practices (21 CFR 1270, 1271).
bottom of page